Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Journey Medical Corporation (DERM)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.0000-0.0500 (-2.44%)
At close: 04:00PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close2.0500
Open2.0800
Bid1.1300 x 1800
Ask2.0000 x 1200
Day's Range1.9300 - 2.1900
52 Week Range1.0500 - 5.9500
Volume9,821
Avg. Volume39,522
Market Cap35.531M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-3.7320
Earnings DateNov 10, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.33
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for DERM

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Journey Medical Corporation
    Analyst Report: Johnson & JohnsonJohnson & Johnson is a diversified healthcare company that develops, manufactures and markets products in three primary lines of business: Pharmaceuticals, Medical Devices and Diagnostics, and Consumer Products.
    Rating
    Fair Value
    Economic Moat
    3 days agoArgus Research
View more
  • GlobeNewswire

    Journey Medical Corporation Appoints Joseph Benesch as Interim Chief Financial Officer

    SCOTTSDALE, Ariz., Jan. 20, 2023 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or the “Company”), a commercial-stage biopharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, today announced that Ernest (Ernie) De Paolantonio has notified the Company that, effective January 27, 2023, he will step down as Chief Financial Officer of Journey Medical to pursue another

  • GlobeNewswire

    Journey Medical Corporation Completes Enrollment in Phase 3 Clinical Trials Evaluating DFD-29 (Minocycline Modified Release Capsules 40 mg) for the Treatment of Papulopustular Rosacea

    Topline data expected in the first half of 2023SCOTTSDALE, Ariz., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ: DERM) (“Journey Medical”), a commercial-stage biopharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, today announced that it has fully enrolled and randomized all of the patients in its Phase 3 clinical program to assess the safety, efficacy and tolerability of D

  • Benzinga

    Journey Medical Touts Positive PK Data For Bacterial Infection Candidate

    Journey Medical Corporation (NASDAQ: DERM) announced PK comparability data of DFD-29 and key updates on the progress of its pivotal, Phase 3 study of DFD-29 for papulopustular rosacea in collaboration with Dr. Reddy's Laboratories Ltd (NYSE: RDY). Papulopustular rosacea is associated with "whitehead" pustules, pus-filled blemishes, and red, swollen bumps. The PK study was designed as a comparative bioavailability study of DFD-29 (Minocycline Modified Release Capsules 40 mg) versus Solodyn (Minoc

Advertisement
Advertisement